Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting

Por Sikov, William M.
Publicado em 2014

Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer

Por Merriam, Priscilla, Sikov, William M
Publicado em 2011

Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy

Por Regen-Tuero, Helaina C., Ward, Robert C., Sikov, William M., Littrup, Peter J.
Publicado no Radiol Imaging Cancer (2021)

Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study

Por Schumacher, Andrew, Sikov, William M., Quesenberry, Matthew I., Safran, Howard, Khurshid, Humera, Mitchell, Kristen M., Olszewski, Adam J.
Publicado no PLoS One (2017)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

Por Cheng, Huan, Bai, Yalai, Sikov, William, Sinclair, Natalie, Bossuyt, Veerle, Abu-Khalaf, Maysa M, Harris, Lyndsay N, Rimm, David L
Publicado em 2014

Impact of Race, Ethnicity and BMI on Achievement of Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer: A Pooled Analysis of Four Prospective Allianc...

Por Warner, Erica T., Ballman, Karla V., Strand, Carrie, Boughey, Judy, Buzdar, Aman U., Carey, Lisa A., Sikov, William M., Partridge, H.
Publicado no Breast Cancer Res Treat (2016)

Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer

Por Brodsky, Alexander S., Xiong, Jinjun, Yang, Dongfang, Schorl, Christoph, Fenton, Mary Anne, Graves, Theresa A., Sikov, William M., Resnick, Murray B., Wang, Yihong
Publicado no BMC Cancer (2016)

Axillary Management of Stage II/III Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-positive) and CALGB 40603 (Triple-negative)

Por Ollila, David W, Cirrincione, Constance T, Berry, Donald A, Carey, Lisa A, Sikov, William M, Hudis, Clifford A, Winer, Eric P, Golshan, Mehra
Publicado no J Am Coll Surg (2017)

Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates: Surgical Results From C...

Por Golshan, Mehra, Cirrincione, Constance T., Sikov, William M., Berry, Donald A., Jasinski, Sara, Weisberg, Tracey F., Somlo, George, Hudis, Clifford, Winer, Eric, Ollila, David W.
Publicado no Ann Surg (2015)

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Por Golshan, Mehra, Cirrincione, Constance T., Sikov, William M., Carey, Lisa A., Berry, Donald A., Overmoyer, Beth, Henry, Nora L., Somlo, George, Port, Elisa, Burstein, Harold J., Hudis, Clifford, Winer, Eric, Ollila, David W.
Publicado no Breast Cancer Res Treat (2016)

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

Por Varadan, Vinay, Gilmore, Hannah, Miskimen, Kristy L.S., Tuck, David, Parsai, Shikha, Awadallah, Amad, Krop, Ian E., Winer, Eric P., Bossuyt, Veerle, Somlo, George, Abu-Khalaf, Maysa M., Fenton, Mary Anne, Sikov, William, Harris, Lyndsay N.
Publicado no Clin Cancer Res (2016)

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)

Por Ligibel, Jennifer A., Cirrincione, Constance T., Liu, Minetta, Citron, Marc, Ingle, James N., Gradishar, William, Martino, Silvana, Sikov, William, Michaelson, Richard, Mardis, Elaine, Perou, Charles M., Ellis, Matthew, Winer, Eric, Hudis, Clifford A., Berry, Donald, Barry, William T.
Publicado no J Natl Cancer Inst (2015)

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial

Por Golshan, Mehra, Loibl, Sibylle, Wong, Stephanie M., Houber, Jens Bodo, O’Shaughnessy, Joyce, Rugo, Hope S., Wolmark, Norman, McKee, Mark D., Maag, David, Sullivan, Danielle M., Metzger-Filho, Otto, Von Minckwitz, Gunter, Geyer, Charles E., Sikov, William M., Untch, Michael
Publicado no JAMA Surg (2020)

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Resp...

Por Sikov, William M., Berry, Donald A., Perou, Charles M., Singh, Baljit, Cirrincione, Constance T., Tolaney, Sara M., Kuzma, Charles S., Pluard, Timothy J., Somlo, George, Port, Elisa R., Golshan, Mehra, Bellon, Jennifer R., Collyar, Deborah, Hahn, Olwen M., Carey, Lisa A., Hudis, Clifford A., Winer, Eric P.
Publicado no J Clin Oncol (2015)

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer

Por Braman, Nathaniel, Prasanna, Prateek, Whitney, Jon, Singh, Salendra, Beig, Niha, Etesami, Maryam, Bates, David D. B., Gallagher, Katherine, Bloch, B. Nicolas, Vulchi, Manasa, Turk, Paulette, Bera, Kaustav, Abraham, Jame, Sikov, William M., Somlo, George, Harris, Lyndsay N., Gilmore, Hannah, Plecha, Donna, Varadan, Vinay, Madabhushi, Anant
Publicado no JAMA Netw Open (2019)

Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Rando...

Por Filho, Otto Metzger, Stover, Daniel G., Asad, Sarah, Ansell, Peter J., Watson, Mark, Loibl, Sibylle, Geyer, Charles E., Bae, Junu, Collier, Katharine, Cherian, Mathew, O’Shaughnessy, Joyce, Untch, Michael, Rugo, Hope S., Huober, Jens B., Golshan, Mehra, Sikov, William M., von Minckwitz, Gunter, Rastogi, Priya, Maag, David, Wolmark, Norman, Denkert, Carsten, Symmans, W. Fraser
Publicado no JAMA Oncol (2021)

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

Por Basch, Ethan, Dueck, Amylou C., Rogak, Lauren J., Minasian, Lori M., Kelly, William Kevin, O’Mara, Ann M., Denicoff, Andrea M., Seisler, Drew, Atherton, Pamela J., Paskett, Electra, Carey, Lisa, Dickler, Maura, Heist, Rebecca S., Himelstein, Andrew, Rugo, Hope S., Sikov, William M., Socinski, Mark A., Venook, Alan P., Weckstein, Douglas J., Lake, Diana E., Biggs, David D., Freedman, Rachel A., Kuzma, Charles, Kirshner, Jeffrey J., Schrag, Deborah
Publicado no JAMA Oncol (2017)

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Por Bossuyt, V., Provenzano, E., Symmans, W. F., Boughey, J. C., Coles, C., Curigliano, G., Dixon, J. M., Esserman, L. J., Fastner, G., Kuehn, T., Peintinger, F., von Minckwitz, G., White, J., Yang, W., Badve, S., Denkert, C., MacGrogan, G., Penault-Llorca, F., Viale, G., Cameron, D., Earl, Helena, Alba, Emilio, Lluch, Ana, Albanell, Joan, Amos, Keith, Biernat, Wojciech, Bonnefoi, Hervé, Buzdar, Aman, Cane, Paul, Pinder, Sarah, Carson, Lesley, Dickson-Witmer, Diana, Gong, Gyungyub, Green, Jimmy, Hsu, Chih-Yi, Tseng, Ling-Ming, Kroep, Judith, Leitch, A. Marilyn, Sarode, Venetia, Mamounas, Eleftherios, Marcom, Paul Kelly, Nuciforo, Paolo, Paik, Soonmyung, Peg, Vicente, Peston, David, Pierga, Jean-Yves, Quintela-Fandino, Miguel, Salgado, Roberto, Sikov, William, Thomas, Jeremy, Unzeitig, Gary, Wesseling, Jelle
Publicado no Ann Oncol (2015)